Log In
BCIQ
Print this Print this
 

SB1317, TG02

  Manage Alerts
Collapse Summary General Information
Company S*BIO Pte. Ltd.
DescriptionOrally-available inhibitor of FMS-like tyrosine kinase 3 (FLT3) and cyclin dependent kinase (CDK)
Molecular Target FMS-like tyrosine kinase 3 (FLT3) (CD135) ; Cyclin dependent kinase (CDK)
Mechanism of ActionCyclin dependent kinase (CDK) inhibitor; FMS-like tyrosine kinase 3 (FLT3) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$112.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/26/2009

$112.5M

Undisclosed

Undisclosed

Get a free BioCentury trial today